Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis
Eur J Clin Pharmacol
.
2020 Jul;76(7):1045-1047.
doi: 10.1007/s00228-020-02877-1.
Epub 2020 May 6.
Authors
Donald Mattison
1
2
,
Christopher Gravel
1
3
4
,
Daniel Krewski
1
3
5
,
Laurent Azoulay
4
6
7
,
Blánaid Hicks
8
,
Antonios Douros
9
10
11
Affiliations
1
School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
2
Risk Sciences International, Hilton Head Island, SC, USA.
3
Risk Sciences International, Ottawa, ON, Canada.
4
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
5
McLaughlin Center for Population Health Risk Assessment, University of Ottawa, Ottawa, ON, Canada.
6
Centre for Clinical Epidemiology, Lady Davis Institute, 3755 Cote Ste-Catherine, H-492, Montreal, QC, H3T 1E2, Canada.
7
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.
8
Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK.
9
Centre for Clinical Epidemiology, Lady Davis Institute, 3755 Cote Ste-Catherine, H-492, Montreal, QC, H3T 1E2, Canada. antonios.douros@mcgill.ca.
10
Department of Medicine, McGill University, Montreal, QC, Canada. antonios.douros@mcgill.ca.
11
Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany. antonios.douros@mcgill.ca.
PMID:
32377758
DOI:
10.1007/s00228-020-02877-1
No abstract available
Publication types
Letter
MeSH terms
Administration, Oral
Adverse Drug Reaction Reporting Systems
Anticoagulants / adverse effects*
Gastroesophageal Reflux / chemically induced*
Humans
Pharmacovigilance
Substances
Anticoagulants
Grants and funding
22185/CRUK_/Cancer Research UK/United Kingdom